Skip to search formSkip to main contentSkip to account menu

GS-9450

Known as: LB-84451, LB84451 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Nivocasan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
126 A PHASE-2B TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A CASPASE INHIBITOR GS-9450, IN ADULTS FAILING PEG/RBV THERAPY FOR CHRONIC HCV INFECTION
2010
2010
273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION
2010
2010
84 SAFETY, TOLERABILITY AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)
2010
2010
745 A DRUG INTERACTION STUDY EVALUATING THE COADMINISTRATION OF GS-9450, A NOVEL CASPASE INHIBITOR, AND THE FIXED-DOSE COMBINATION OF EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN HEALTHY…
2009
2009
405 SERUM LEVELS OF CHEMERIN, VASPIN, VISFATIN AND SPECAM-1 IN PATIENTS WITH CHRONIC HEPATITIS C
2009
2009
250 GS-9450: A NOVEL LIVER-TARGETED CASPASE INHIBITOR THAT BLOCKS APOPTOTIC SIGNALING IN HEPATOCYTES
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)